Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices.
- Author:
Sung Chul PARK
1
;
Hoon Jai CHUN
Author Information
1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
- Publication Type:Review
- Keywords:
Stomach neoplasms;
Drug therapy
- MeSH:
Antibodies, Monoclonal, Humanized;
Asia;
Bridged Compounds;
Camptothecin;
Chemoradiotherapy, Adjuvant;
Chemotherapy, Adjuvant;
Deoxycytidine;
Epirubicin;
Europe;
Fluorouracil;
Humans;
Korea;
Organoplatinum Compounds;
Platinum;
Receptor, Epidermal Growth Factor;
Stomach Neoplasms;
Taxoids;
United States
- From:Gut and Liver
2013;7(4):385-393
- CountryRepublic of Korea
- Language:English
-
Abstract:
No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1 or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum, taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine, such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.
